Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP1 | P09874 | 2/20 | 0.39 |
| ▸ | PARP15 | Q460N3 | 1/20 | 0.39 |
| ▸ | PARP3 | Q9Y6F1 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | TNKS | O95271 | 1/20 | 0.30 |
| ▸ | TNKS2 | Q9H2K2 | 1/20 | 0.30 |
| ▸ | PARP2 | Q9UGN5 | 1/20 | 0.30 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | ALPL | P05186 | 1/20 | 0.30 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9947019 | 0.70 | — | — | |
| SCHEMBL14045627 | 0.68 | TSHR (0.47) | TSHRMEN1ALPLMAPK1KMT2A | |
| SCHEMBL16847016 | 0.65 | PNMT (0.39) | TSHRMEN1ALPLMAPK1KMT2A | |
| SCHEMBL19153185 | 0.64 | PARP1 (0.46) | PARP1PARP15PARP3TNKSTNKS2 | |
| SCHEMBL22854378 | 0.61 | PNMT (0.39) | TSHRMEN1ALPLMAPK1KMT2A | |
| SCHEMBL18237823 | 0.60 | HCAR2 (0.35) | — | |
| SCHEMBL21388626 | 0.60 | HCAR2 (0.35) | TSHRMEN1KMT2A | |
| SCHEMBL12094414 | 0.60 | WNT3A (0.38) | TSHRTNKS2MEN1ALPLMAPK1 | |
| SCHEMBL18770377 | 0.60 | — | — | |
| SCHEMBL13151082 | 0.59 | PNMT (0.37) | MEN1MAPK1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7589204-B2 | Indane compounds as CCR5 antagonists | SMITHKLINE BEECHAM CORPORATION (US) | 2009-09-15 | — | — | US | disclosed |
| US-20090187021-A1 | INDANE COMPOUNDS AS CCR5 ANTAGONISTS | YOUNGMAN MICHAEL | 2009-07-23 | — | — | US | disclosed |
| US-7271172-B2 | Pyrrolidine and azetidine compounds as CCR5 antagonists | SMITHKLINE BEECHAM CORPORATION (US) | 2007-09-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090187021-A1 | INDANE COMPOUNDS AS CCR5 ANTAGONISTS | CCR5, CCL5, IDO1 | PARP1 2138/4885PARP15 555/4885PARP3 1454/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.